Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226201 | 0.86 | RAB9A (0.52) | CYP4F2CYP4A11RAB9ANPC1CLK1 | |
| SCHEMBL10956809 | 0.85 | NPC1 (0.55) | CYP4F2CYP4A11RAB9ANPC1POLB | |
| SCHEMBL1405119 | 0.82 | RAB9A (0.50) | RAB9ANPC1CHRM5CHRM1CHRM4 | |
| SCHEMBL27605521 | 0.82 | RAB9A (0.51) | RAB9ANPC1CHRM5CHRM1CHRM4 | |
| SCHEMBL3665814 | 0.81 | KDM4E (0.39) | CYP4F2CYP4A11RAB9ANPC1CLK1 | |
| SCHEMBL81136 | 0.80 | FABP4 (0.58) | RAB9ANPC1CHRM5CHRM1CHRM4 | |
| SCHEMBL846867 | 0.80 | CTSB (0.58) | CYP4F2CYP4A11 | |
| SCHEMBL25315569 | 0.80 | CYP4F2 (0.47) | CYP4F2CYP4A11RAB9ANPC1CLK1 | |
| SCHEMBL22590446 | 0.80 | RIPK1 (0.48) | CYP4F2CYP4A11RAB9ANPC1TP53 | |
| SCHEMBL3186208 | 0.80 | CYP3A4 (0.58) | CYP4F2CYP4A11RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010041271-A2 | PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF | USV LIMITED (IN) | 2010-04-15 | — | — | WO | claimed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | disclosed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | disclosed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8609871-B2 | Process for production of optically active amine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1100508-B1 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6348485-B1 | ramelteon and one of zolpidem, zopiclone, brotizolam and triazolam | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | CYP4F2 2049/4885CYP4A11 324/4885RAB9A 563/4885 |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | CYP4F2 2049/4885CYP4A11 324/4885RAB9A 563/4885 |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | CYP4F2 1755/4885CYP4A11 834/4885RAB9A 903/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | CYP4F2 2049/4885CYP4A11 324/4885RAB9A 563/4885 |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | CYP4F2 1755/4885CYP4A11 834/4885RAB9A 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.